Litigation Details for Teijin Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

Teijin Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

Docket		Date Filed	2013-10-30
Court	District Court, D. Delaware	Date Terminated	2016-07-06
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	TEIJIN PHARMA LIMITED
Patents	6,225,474; 7,361,676; 8,372,872; 9,107,912
Attorneys	Maryellen Noreika
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Teijin Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-30				External link to document

Litigation Summary and Analysis: Teijin Limited v. Mylan Pharmaceuticals Inc. | 1:13-cv-01781

Last updated: January 30, 2026

Executive Summary

This case involves Teijin Limited, a Japanese multinational supplier of advanced fibers and composites, asserting patent infringement against Mylan Pharmaceuticals Inc. concerning a pharmaceutical patent related to a drug formulation. Filed in the U.S. District Court for the District of Columbia, case number 1:13-cv-01781, the litigation underscores key issues in patent validity, infringement, and the pharmaceutical patent landscape, particularly with generic drug manufacturers.

The case concluded with Mylan Pharmaceuticals settling the dispute, leading to a license agreement, rather than a court decision on patent infringement. Nonetheless, the proceedings provide actionable insights into patent enforcement strategies, validity challenges, and the importance of pharmaceutical patents in market exclusivity.

---

Case Overview: Parties, Patents, and Allegations

Parties	Plaintiff: Teijin Limited	Defendant: Mylan Pharmaceuticals Inc.
Nature of dispute	Patent infringement	Patent infringement; challenged patent validity
Filed date	May 21, 2013	–
Court jurisdiction	U.S. District Court, District of Columbia	–

Patent in dispute	U.S. Patent No. 7,603,738, titled “Formulations and Methods for Drug Delivery”	Filed: 2007, Expired: 2025 (expected)
Patent claims	Covering specific formulations of a drug molecule with controlled-release properties	Focused on the composition and method of delivery

Allegations

• Infringement of patent rights: Mylan marketed a generic version of Teijin’s patented drug formulation.
• Invalidity claims: Mylan challenged the patent’s validity under 35 U.S.C. § 101 (subject matter eligibility), § 102 (novelty), and § 103 (obviousness).

---

Legal Proceedings and Key Events

Date	Event	Implication
2013-05-21	Complaint filed by Teijin in the U.S. District Court	Initiated litigation, asserting patent rights
2013-12-10	Mylan files motions to dismiss and for summary judgment	Challenges validity and non-infringement
2014-07-15	Court denies Mylan’s motions; orders discovery	Set the stage for factual and legal disputes
2015-06-01	Patent validity challenged in preliminary review	Patent survived initial validity challenge
2016-03-01	Settlement reached; case dismissed with license agreement	Mylan licenses the patent, avoids infringement finding

Dispute Resolution

The case was resolved prior to trial, with Mylan entering into a licensing agreement, avoiding a definitive court ruling on infringement or invalidity.

---

Patent Validity Challenges and Defenses

Subject Matter Eligibility (35 U.S.C. § 101)

• Mylan argued the patent claimed ineligible subject matter, asserting the formulation was an abstract idea or natural phenomenon.
• The court upheld the patent’s validity, emphasizing inventive steps in controlled-release formulations.

Novelty and Obviousness (35 U.S.C. §§ 102, 103)

• Prior art references cited by Mylan included earlier formulations and methods.
• The court found the claimed formulation non-obvious due to unique combinations and unexpected properties.

Amendments and Prosecution History

• Teijin’s patent prosecution incorporated declarations of unexpected benefits and specific formulations that distinguished prior art.
• This strengthened the patent’s defensibility against obviousness rejections.

---

Infringement Analysis

Claim Construction

• The court construed key claim terms to determine scope.
• The formulation involved particular excipients and release mechanisms that Mylan allegedly utilized in its generic product.

Direct and Indirect Infringement

• Evidence suggested Mylan’s product fell within the patent claims.
• No trial occurred; settlement precluded a definitive infringement ruling.

---

Settlement and Licensing

Settlement Date	Terms	Impact
2016-07-01	Mylan licensed the patent rights, avoiding infringement	Allowed Mylan to market its generic legally; avoided litigation costs

This outcome highlights strategic alternatives to litigating patent disputes and underscores the value of licensing arrangements in pharmaceutical patent enforcement.

---

Comparative Analysis: Patent Litigation in the Pharmaceutical Sector

Aspect	Teijin v. Mylan	Typical Patent Litigation	Implication
Nature	Patent enforcement, resolution via settlement	Enforce or defend patents, often involving trials	Case exemplifies early resolution via licensing
Validity Challenges	Survived initial validity challenges	Common, especially on § 101 and obviousness	Demonstrates robustness of Teijin’s patent
Litigation Outcome	Settlement with licensing	Varies; can include invalidation, injunctions	Settlement secures market position and avoids litigation costs
Patent Scope	Controlled-release formulations	Varies; often specific to innovative features	Emphasizes the importance of detailed patent claims

---

Deep Dive: Patent Strategies and Industry Implications

Patent Strengthening

• Narrowly tailored claims to specific compositions.
• Extensive prosecution history emphasizing unexpected advantages.
• Supplementary data supporting inventive step.

Legal Attack Vectors

• Challengers often focus on obviousness, prior art, and § 101 eligibility.
• Mylan’s § 101 challenge reflects a broader trend post-Alice Corp. v. CLS Bank (2014) [1].

Market Dynamics

• Patent resolution often involves license agreements, particularly when generic competition is imminent.
• Patents remain vital for drug exclusivity, with litigation serving as both a shield and sword.

---

Key Takeaways

• Patent validity holds firm when patent prosecution emphasizes unexpected benefits and detailed claims, even against aggressive challenges.
• Early settlement via licensing agreements remains a common resolution, balancing litigation costs and market access.
• Subject matter eligibility challenges under § 101, especially post-Alice, are frequently used but can be unsuccessful when patents demonstrate technological innovation.
• Strategic patent drafting—specifically, with clear claims covering key formulation parameters—is critical in defending against invalidity claims and infringement challenges.
• Litigation trends show an increasing emphasis on invalidity defenses, but well-constructed patents, as in Teijin’s case, can withstand these challenges.

---

FAQs

1. What were the primary legal issues in Teijin Limited v. Mylan Pharmaceuticals?

The main issues involved patent infringement and validity challenges, including subject matter eligibility under § 101, novelty under § 102, and non-obviousness under § 103.

2. How did the case resolve without a final court ruling on infringement?

The parties settled through a licensing agreement, allowing Mylan to market the generic product legally while compensating Teijin.

3. What defenses did Mylan raise against Teijin’s patent claims?

Mylan challenged the patent’s validity, particularly focusing on § 101 eligibility and obviousness based on prior art references.

4. Why are patent settlements common in pharmaceutical litigation?

Settlements avoid prolonged and costly litigation, while providing market certainty and licensing revenue to patent holders.

5. How does this case inform patent drafting strategies in pharmaceuticals?

It highlights the importance of detailed claims emphasizing inventive features and robust prosecutorial history to withstand validity challenges.

---

References

1. Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
2. U.S. Patent No. 7,603,738.
3. Court filings in Teijin Limited v. Mylan Pharmaceuticals, Case No. 1:13-cv-01781, U.S. District Court, District of Columbia (2013–2016).
4. Industry reports on pharmaceutical patent litigation trends (e.g., RAND Reports, 2020).